Skip to main navigation Skip to search Skip to main content

Role of the pituitary-adrenal axis in granulocyte-colony stimulating factor-induced neuroprotection against hypoxia-ischemia in neonatal rats

Research output: Contribution to journalArticlepeer-review

Abstract

Several reports indicate that the activity of the hypothalamic-pituitary-adrenal axis (HPA) is increased after a brain insult and that its down-regulation can improve detrimental outcomes associated with ischemic brain injuries. Granulocyte-colony stimulating factor (G-CSF) is a neuroprotective drug shown in the naïve rat to regulate hormones of the HPA axis. In this study we investigate whether G-CSF confers its neuroprotective properties by influencing the HPA response after neonatal hypoxia-ischemia (HI). Following the Rice-Vannucci model, seven day old rats (P7) were subjected to unilateral carotid ligation followed by 2.5. h of hypoxia. To test our hypothesis, metyrapone was administered to inhibit the release of rodent specific glucocorticoid, corticosterone, at the adrenal level. Dexamethasone, a synthetic glucocorticoid, was administered to agonize the effects of corticosterone. Our results show that both G-CSF and metyrapone significantly reduced infarct volume while dexamethasone treatment did not reduce infarct size even when combined with G-CSF. The protective effects of G-CSF do not include blood brain barrier preservation as suggested by the brain edema results. G-CSF did not affect the pituitary released adrenocorticotropic hormone (ACTH) levels in the blood plasma at 4. h, but suppressed the increase of corticosterone in the blood. The administration of G-CSF and metyrapone increased weight gain, and significantly reduced the Bax/Bcl-2 ratio in the brain while dexamethasone reversed the effects of G-CSF. The combination of G-CSF and metyrapone significantly decreased caspase-3 protein levels in the brain, and the effect was antagonized by dexamethasone. We report that G-CSF is neuroprotective in neonatal HI by reducing infarct volume, by suppressing the HI-induced increase of the Bax/Bcl-2 ratio, and by decreasing corticosterone in the blood. Metyrapone was able to confer similar neuroprotection as G-CSF while dexamethasone reversed the effects of G-CSF. In conclusion, we show that decreasing HPA axis activity is neuroprotective after neonatal HI, which can be conferred by administering G-CSF. © 2012 Elsevier Inc.
Original languageEnglish
Pages (from-to)29-37
Number of pages9
JournalNeurobiology of Disease
Volume47
Issue number1
DOIs
StatePublished - Jul 2012

ASJC Scopus Subject Areas

  • Neurology

Keywords

  • Bax
  • Bcl-2
  • Caspase-3
  • Dexamethasone
  • G-CSF
  • HPA axis
  • Hypoxia-ischemia
  • Metyrapone
  • Pituitary-Adrenal System/drug effects
  • Corticosterone/blood
  • Enzyme Inhibitors/pharmacology
  • Brain Edema/physiopathology
  • Brain/drug effects
  • Hypoxia-Ischemia, Brain/metabolism
  • Granulocyte Colony-Stimulating Factor/pharmacology
  • Adrenocorticotropic Hormone/blood
  • bcl-2-Associated X Protein/drug effects
  • Animals, Newborn
  • Down-Regulation/drug effects
  • Rats
  • Neuroprotective Agents/pharmacology
  • Caspase 3/drug effects
  • Glucocorticoids/pharmacology
  • Rats, Sprague-Dawley
  • Proto-Oncogene Proteins c-bcl-2/drug effects
  • Animals
  • Dexamethasone/pharmacology
  • Hypothalamo-Hypophyseal System/drug effects
  • Metyrapone/pharmacology

Cite this